Combination of antiviral drugs inhibits SARS-CoV- 2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture

Wang, Xuanting; Sacramento, Carolina Q.; Jockusch, Steffen; Chaves, Otávio Augusto; Tao, Chuanjuan; Fintelman-Rodrigues, Natalia; Chien, Minchen; Temerozo, Jairo R.; Li, Xiaoxu; Kumar, Shiv; Xie, Wei; Patel, Dinshaw J.; Meyer, Cindy; Garzia, Aitor; Tuschi, Thomas; Bozza, Patricia T.; Russo, James J.; Souza, Thiago Moreno L.; Ju, Jingyue.
Artículo en Inglés | ARCA | ID: arc-53619

Documentos relacionados

  1. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture.
  2. Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics.
  3. Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19.
  4. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
  5. Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
  6. The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters.
  7. Synergistic Antiviral Activity of Pamapimod and Pioglitazone against SARS-CoV-2 and Its Variants of Concern.
  8. Impaired local intrinsic immunity to SARS-CoV-2 infection in severe COVID-19.
  9. T-cell responses and therapies against SARS-CoV-2 infection.
  10. Sertraline Is an Effective SARS-CoV-2 Entry Inhibitor Targeting the Spike Protein.